key: cord-0734336-8mkh50oy
authors: Baldi, Bruno Guedes; Amaral, Alexandre Franco; de Figueiredo Braga Colares, Phillipe; Kairalla, Ronaldo Adib; de Oliveira, Martina Rodrigues; Carvalho, Carlos Roberto Ribeiro
title: COVID‐19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors
date: 2020-09-18
journal: Am J Med Genet A
DOI: 10.1002/ajmg.a.61877
sha: f9a0af322ab6564488589dd61107e4aef4108d46
doc_id: 734336
cord_uid: 8mkh50oy

nan

COVID-19 and lymphangioleiomyomatosis: Experience at a reference center and the potential impact of the use of mTOR inhibitors

To the Editor,

We read with great interest the article entitled "Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy" by Peron et al. (2020) , which described the features and outcomes of coronavirus disease-19 in patients with tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM) in Italy, and the potential role of mTOR inhibitors in such infection. Here, we present our experience of patients with LAM and COVID-19, with an emphasis on the potential influence of the use of mTOR inhibitors.

This was a retrospective study that included patients with LAM who were being followed-up in our center between March 1, 2020 and August 20, 2020. Patients from all the regions of Brazil were assessed. Data was obtained during regular visits or through phone calls.

A total of 143 women with LAM, including 114 (79.7%) sporadic-LAM and 29 (20.3%) associated with TSC, were included in the study.

Seventy-three (51%; 95% confidence interval: 42.9-59.1%) patients were using mTOR inhibitors (69 on sirolimus, mean dose of 2 ± 1 mg/ day, and four on everolimus, all receiving 10 mg/day). Six (4.2%; 95% confidence interval: 1.9-8.8%) nonsmoking patients had COVID-19-compatible symptoms, and a positive polymerase chain reaction (PCR) that confirmed the diagnosis of the infection ( Figure 1 ); three (4.1%) in patients who used mTOR inhibitors and three (4.3%) in those who did not use these drugs (p = .715). Among the six patients who had the diagnosis of COVID-19 confirmed, three (50%) had renal angiomyolipoma and none of them had any other comorbidity. Only one patient required hospital admission due to hypoxemia. All the patients fully recovered from COVID-19. Demographic, clinical, and functional characteristics of those with a confirmed diagnosis of COVID-19 are presented in Table 1 . The mean age was 52 ± 9 years and the main clinical manifestations were asthenia (100%), fever (50%), headache (50%), and anosmia (50%). Additionally, it was recommended to maintain the use of mTOR inhibitors during the outbreak unless there is an active infection, and not to start taking these drugs to prevent or treat COVID-19 (The LAM Foundation COVID-19 Statement, 2020). Our findings suggest that the use of mTOR inhibitors do not increase the risk of symptomatic COVID-19, as the frequency of such infection was similar between patients who were using this class of drugs and those who were not.

Our study has limitations that need to be addressed. This was a single-center analysis, with a small number of COVID-19 patients.

However, it was performed at a reference center where patients with LAM from all the regions of Brazil were followed up. Additionally, we did not include asymptomatic COVID-19 patients confirmed by PCR, which may have underestimated the real frequency of the infection in the present study.

In conclusion, our study suggests that LAM is not associated with a higher susceptibility to serious COVID-19 complications and that F I G U R E 1 Axial computed tomography images show regular and diffuse pulmonary cysts (a-d), ground-glass opacities (c), and an area of consolidation (d) in the periphery of the lower lobes in a woman with LAM using everolimus

Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis diagnosis and management

Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: The experience of a TSC clinic in Italy

An open question: Is it rational to inhibit mTordependent pathway as COVID-19 therapy?

The LAM Foundation COVID-19 Statement

Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines